Clinical Trial Update: A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing GME751 to pembrolizumab (Keytruda) in adults with untreated metastatic non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• GME751
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Sandoz | Conditions: Metastatic NSCLC | Phase 3 | Status: COMPLETED